Syra Health (SYRA) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 42% year-over-year to $2.3M, driven by healthcare workforce and population health segments.

• Net loss for Q3 2024 was $417,535 ($0.06 per share), a 69% sequential reduction from Q2 2024, but up from $354,376 in Q3 2023.

• Gross margin was 30% in Q3 2024, down from 35% in Q3 2023, but up from 17.8% in Q2 2024 due to operational efficiencies.

• Expanded product offerings, including the Serenity/Syrenity mental health app and SyraBot AI chatbot, supporting innovation and market expansion.

• Completed a $2.1M capital raise in September 2024 to enhance financial flexibility and support growth initiatives.

Financial highlights

• Q3 2024 revenue: $2.3M (up 42% year-over-year); nine months: $6.0M (up 59%).

• Gross profit: $668K in Q3 2024 (margin 30%); nine months: $1.2M (margin 20%).

• Net loss: $417,535 in Q3 2024; nine months: $3.25M.

• Operating expenses: $1.1M in Q3 2024, down 37% sequentially, up 22.2% year-over-year.

• Cash on hand: $2.7M as of September 30, 2024, with a projected two-year capital runway.

Outlook and guidance

• Targeting profitability by 2025 through continued revenue growth, cost optimization, and innovation.

• Management expects existing liquidity and cash from sales may not be sufficient for the next twelve months; additional financing may be required.

• Focused on expanding in federal and global mental health markets and leveraging AI technology.